![]() Once a manuscript is accepted contributors will be provided with an electronic pdf proof, and corrections must be returned within three working days. ![]() Authors will normally be notified of acceptance, rejection, or need for revision within 6 weeks of submission. Papers of high interest will be sent out for external review. The editorial office will return to authors within 3 weeks, whenever possible, all papers that are found to be of insufficient priority for further consideration. The editorial office will rapidly review manuscripts in order that new findings may appear with minimum delay. Studies should be carried out in accordance with the relevant national and local guidelines. Papers disregarding the welfare of experimental animals will be rejected. Papers reporting clinical studies should, where appropriate, contain a statement that they have been carried out with ethics committee approval. Manuscripts should be submitted with a letter specifying that the report is not under consideration for publication elsewhere and that all named authors have agreed to its submission. The criteria for acceptance are originality and high scientific quality. Guide for Authors updated 29th November 2022Īnnals of Oncology Via Ginevra 4 CH-6900 Lugano Switzerland Telephone: +41 (0)9/10Į-mail: Annals of Oncology publishes manuscripts that describe new findings of particular significance in any area related to clinical oncology and clinically-oriented basic cancer research. Requests about the status of your manuscript.With a large international editorial board of experts who are leaders in their fields, Annals of Oncology aims at delivering the best communication on the fast moving, and continually evolving, global oncology landscape. ![]() Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |